A Clinician’s Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis

April W. Armstrong, Michael Bukhalo, Andrew Blauvelt

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Many of the molecular pathways associated with psoriasis pathogenesis are also involved in host defense mechanisms that protect against common pathogens. Candida can stimulate the production of cytokines that trigger or exacerbate psoriasis, and many systemic psoriasis treatments may put patients at increased risk for developing oral, cutaneous, and genitourinary candidiasis. Therefore, dermatologists should regularly screen patients with psoriasis for signs of Candida infection, and take steps to effectively treat these infections to prevent worsening of psoriasis symptoms. This review provides an overview of candidiasis epidemiology in patients with psoriasis, followed by a primer on the diagnosis and treatment of superficial Candida infections, with specific guidance for patients with psoriasis. Candidiasis in patients with psoriasis typically responds to topical or oral antifungal therapy. While biologic agents used to treat moderate-to-severe psoriasis, such as tumor necrosis factor-α inhibitors and interleukin-17 inhibitors, are known to increase patients’ risk of developing localized candidiasis, the overall risk of infection is low, and candidiasis can be effectively managed in most patients while receiving systemic psoriasis therapies. Thus, the development of candidiasis does not usually necessitate changes to psoriasis treatment regimens.

Original languageEnglish (US)
Pages (from-to)329-336
Number of pages8
JournalAmerican Journal of Clinical Dermatology
Volume17
Issue number4
DOIs
StatePublished - Aug 1 2016
Externally publishedYes

Fingerprint

Candidiasis
Psoriasis
Candida
Therapeutics
Infection
Cutaneous Candidiasis
Interleukin-17
Biological Factors
Epidemiology
Tumor Necrosis Factor-alpha
Cytokines

ASJC Scopus subject areas

  • Dermatology

Cite this

A Clinician’s Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis. / Armstrong, April W.; Bukhalo, Michael; Blauvelt, Andrew.

In: American Journal of Clinical Dermatology, Vol. 17, No. 4, 01.08.2016, p. 329-336.

Research output: Contribution to journalArticle

Armstrong, April W. ; Bukhalo, Michael ; Blauvelt, Andrew. / A Clinician’s Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis. In: American Journal of Clinical Dermatology. 2016 ; Vol. 17, No. 4. pp. 329-336.
@article{8efc8e875dfa4e508ad22d7877376e31,
title = "A Clinician’s Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis",
abstract = "Many of the molecular pathways associated with psoriasis pathogenesis are also involved in host defense mechanisms that protect against common pathogens. Candida can stimulate the production of cytokines that trigger or exacerbate psoriasis, and many systemic psoriasis treatments may put patients at increased risk for developing oral, cutaneous, and genitourinary candidiasis. Therefore, dermatologists should regularly screen patients with psoriasis for signs of Candida infection, and take steps to effectively treat these infections to prevent worsening of psoriasis symptoms. This review provides an overview of candidiasis epidemiology in patients with psoriasis, followed by a primer on the diagnosis and treatment of superficial Candida infections, with specific guidance for patients with psoriasis. Candidiasis in patients with psoriasis typically responds to topical or oral antifungal therapy. While biologic agents used to treat moderate-to-severe psoriasis, such as tumor necrosis factor-α inhibitors and interleukin-17 inhibitors, are known to increase patients’ risk of developing localized candidiasis, the overall risk of infection is low, and candidiasis can be effectively managed in most patients while receiving systemic psoriasis therapies. Thus, the development of candidiasis does not usually necessitate changes to psoriasis treatment regimens.",
author = "Armstrong, {April W.} and Michael Bukhalo and Andrew Blauvelt",
year = "2016",
month = "8",
day = "1",
doi = "10.1007/s40257-016-0206-4",
language = "English (US)",
volume = "17",
pages = "329--336",
journal = "American Journal of Clinical Dermatology",
issn = "1175-0561",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - A Clinician’s Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis

AU - Armstrong, April W.

AU - Bukhalo, Michael

AU - Blauvelt, Andrew

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Many of the molecular pathways associated with psoriasis pathogenesis are also involved in host defense mechanisms that protect against common pathogens. Candida can stimulate the production of cytokines that trigger or exacerbate psoriasis, and many systemic psoriasis treatments may put patients at increased risk for developing oral, cutaneous, and genitourinary candidiasis. Therefore, dermatologists should regularly screen patients with psoriasis for signs of Candida infection, and take steps to effectively treat these infections to prevent worsening of psoriasis symptoms. This review provides an overview of candidiasis epidemiology in patients with psoriasis, followed by a primer on the diagnosis and treatment of superficial Candida infections, with specific guidance for patients with psoriasis. Candidiasis in patients with psoriasis typically responds to topical or oral antifungal therapy. While biologic agents used to treat moderate-to-severe psoriasis, such as tumor necrosis factor-α inhibitors and interleukin-17 inhibitors, are known to increase patients’ risk of developing localized candidiasis, the overall risk of infection is low, and candidiasis can be effectively managed in most patients while receiving systemic psoriasis therapies. Thus, the development of candidiasis does not usually necessitate changes to psoriasis treatment regimens.

AB - Many of the molecular pathways associated with psoriasis pathogenesis are also involved in host defense mechanisms that protect against common pathogens. Candida can stimulate the production of cytokines that trigger or exacerbate psoriasis, and many systemic psoriasis treatments may put patients at increased risk for developing oral, cutaneous, and genitourinary candidiasis. Therefore, dermatologists should regularly screen patients with psoriasis for signs of Candida infection, and take steps to effectively treat these infections to prevent worsening of psoriasis symptoms. This review provides an overview of candidiasis epidemiology in patients with psoriasis, followed by a primer on the diagnosis and treatment of superficial Candida infections, with specific guidance for patients with psoriasis. Candidiasis in patients with psoriasis typically responds to topical or oral antifungal therapy. While biologic agents used to treat moderate-to-severe psoriasis, such as tumor necrosis factor-α inhibitors and interleukin-17 inhibitors, are known to increase patients’ risk of developing localized candidiasis, the overall risk of infection is low, and candidiasis can be effectively managed in most patients while receiving systemic psoriasis therapies. Thus, the development of candidiasis does not usually necessitate changes to psoriasis treatment regimens.

UR - http://www.scopus.com/inward/record.url?scp=84979742694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979742694&partnerID=8YFLogxK

U2 - 10.1007/s40257-016-0206-4

DO - 10.1007/s40257-016-0206-4

M3 - Article

AN - SCOPUS:84979742694

VL - 17

SP - 329

EP - 336

JO - American Journal of Clinical Dermatology

JF - American Journal of Clinical Dermatology

SN - 1175-0561

IS - 4

ER -